



October 12<sup>th</sup> 2020 | CannPal Animal Therapeutics Limited | ASX: CP1  
ASX ANNOUNCEMENT

## ***CannPal Commences DermaCann® Product Registration in South Africa***

### **Key Highlights**

- CannPal has commenced the application process for the registration of DermaCann® as a herbal supplement with the South African Department of Agriculture, Forestry and Fisheries;
- The registration of DermaCann® in South Africa will complement the Company's Australian and New Zealand regulatory dossiers, presently being drafted for submission;
- The decision to submit a registration dossier in South Africa follows recent positive changes to the CBD (cannabidiol) legislation permitting the sale of certain products containing CBD within set parameters of which DermaCann® is expected to be compliant;
- The Company has also entered into an agreement to commence manufacturing activities in the United States for the commercialisation of DermaCann® in the U.S in early 2021.

---

**October 12<sup>th</sup> 2020:** Animal health company **CannPal Animal Therapeutics Limited (ASX:CP1)** ("CannPal" or "the Company") is pleased to announce that it has commenced the application process for the registration and Commercialisation of DermaCann® within the animal veterinary market in South Africa.

CannPal is working with a local partner to provide regulatory support in relation to the Company's application for the registration of DermaCann® with the Department of Agriculture, Forestry and Fisheries (DAFF) to be registered as a herbal supplement for commercialisation within the country.

Recent legislative changes for CBD have provided the opportunity for CannPal to leverage its DermaCann® dataset for product registration in the South African market for legal sale through veterinary channels, with shorter approval timelines to fast track commercialisation.

The registration of DermaCann® in South Africa will complement the Company's Australian and New Zealand regulatory dossiers presently being drafted for submission.

There are an estimated 2.5 million medicalized dogs in South Africa and an estimated 20% suffering from atopic dermatitis or skin disease, providing an ideal pilot regulatory market for launching DermaCann® through the veterinary channel ahead of Australia and New Zealand registrations.

### **DermaCann® U.S Commercialisation**

The Company is also pleased to announce that it has entered into a manufacturing agreement with a U.S based Company, Vetio Animal Health, to commence manufacturing activities for the commercialisation of DermaCann® in the United States in early 2021.

Vetio is a leading Contract Development and Manufacturing Organisation in America dedicated to animal health with a focus on cGMP compliance (current Good Manufacturing Practices) to the highest industry standards.

Certain states in America have introduced favourable legislation for pet products containing or consisting of hemp-derived cannabidiol, which allows CannPal an opportunity to leverage its robust product dossier to capitalise on both the evolving hemp-derived CBD market headwinds, as well as the traditional canine skin health market in the U.S.

The global canine skin and dermatitis market is worth over US\$1b globally, and the launch of DermaCann® will provide the veterinary market with a unique CBD-derived and clinically validated product to be used as a beneficial therapy in a canine atopic dermatitis management regimen.

CannPal has continued discussions with leading animal health partners for the commercialisation of DermaCann® in various markets, including South Africa and the United States.

#### **CannPal Managing Director, Layton Mills**

*“We have had DermaCann® in development for over 3 years now and in that time we’ve built a robust product dossier with a novel formulation, compelling dataset and strong Intellectual Property. To our knowledge, this will be the only clinically validated oral CBD-derived pet nutraceutical for skin health in dogs. We look forward to fast tracking the commercialisation for this exciting product in the coming months.”*

#### **About CannPal Animal Therapeutics**

CannPal Animal Therapeutics Limited (ASX: CP1) is an animal health Company with a mission to provide pet owners and veterinarians with access to high quality, evidence based, plant derived therapeutic products to promote better health and well-being for animals.

Presently, the Company is focused on the development of pharmaceutical and nutraceutical products for dogs, for commercialisation in various markets around the world, using compounds derived from the hemp and cannabis plant.

To learn more please visit: [www.cannpal.com](http://www.cannpal.com)

#### **ENDS**

This announcement has been approved and authorised to be given to ASX by Mr Geoff Starr, the Chairman of CannPal Animal Therapeutics Limited.

---

#### **For further information, please contact:**

##### **CannPal Animal Therapeutics**

Layton Mills

Managing Director

M: 0431 302 667

E: [Layton@cannpal.com](mailto:Layton@cannpal.com)